CUAJ, E. 2026. Enfortumab Vedotin (EV) and Pembrolizumab (Pembro) Combination Treatment for Patients with Urological Cancers – Adverse Events (AEs): Management Tool Kit. Canadian Urological Association Journal. 15, 1X (May 2026).